Keiko Suzaki

Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the Susta<scp>IMM</scp> phase 2/3 trial

Mamitaro Ohtsuki, Hideki Fujita, Keiko Suzaki et al. · The Journal of Dermatology · 2019 · 95 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial

Ryuzo Kawamori, Masakazu Haneda, Keiko Suzaki et al. · Diabetes Obesity and Metabolism · 2018 · 42 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes

Daisuke Yabe, Kosuke Shiki, Keiko Suzaki et al. · BMJ Open · 2021 · 28 citations · Full text

Medicine, Endocrinology, Pharmacology +17